Hogg RJ, for the Scientific Planning Committee of the IgA
A randomized, placebo-controlled, multicenter trial evaluating
alternate-day prednisone and fish oil supplements in young
patients with immunoglobulin A nephropathy
Am J Kidney Dis
(Nov) 26:792-796 1995
This paper announces a new multicenter trial for patients less than 30 years
of age with IgA nephropathy and likely indices of progression
(glomerulosclerosis and/or proliferation leading to closure of glomerular
capillary loops and proteinuria greater than 1 g/1.73 m2). The design is a
randomized prospective 3-arm trial. Each arm will receive enalapril if
hypertensive. Arm 1 will get placebo, arm 2 a 2-year tapering regimen of
prednisone (qod, tapered from 60 mg/m2 to 30 mg/m2), and arm 3 will receive a
2-year course of fish oil supplements. Follow up will be three 1.5 hour GFR
measurements based on creatinine clearance yearly for 5 years. The outcome
criterion is a fall in creatinine clearance to less than 70% of baseline.
Patients must have a CCr greater than 70/ml/min/m2 to enter the
Physicians interested in this trial should call the Central Office of the
Southwest Pediatric Nephrology Group at 1-800-345-IGAN.
To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below: